奥本海默:维持Alumis(ALMS.US)评级,由优于大市调整至优于大市评级,目标价由26.00美元调整至25.00美元。Alumis(ALMS.US)公司简介:Alumis Inc是一家临床阶段的生物制药公司,专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。该公司利用其专有的精确数据分析平台、生物学见解、以及在精准医学药物发现、开发和免疫学方面拥有丰富经验的专家团队,通过用靶向...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.